Tokyo Tape
Sign in
← Olympus

Quarterly report · Q2

7733.TEDINET S100PO2O
Period2022-04-01 → 2022-09-30
Filed2022-11-21
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed

Amends S100PKO6.

Key figures · 61
MetricValuePeriodScopeSource row
Revenue¥417.1bn2022-04-01 → 2022-09-30Cons.Revenue IFRS (5-year summary)
Revenue¥224.8bn2022-07-01 → 2022-09-30dCons.Revenue IFRS (5-year summary)
Revenue¥750.1bn2021-04-01 → 2022-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥360.1bn2021-04-01 → 2021-09-30Cons.Revenue IFRS (5-year summary)
Revenue¥193.3bn2021-07-01 → 2021-09-30dCons.Revenue IFRS (5-year summary)
Operating income¥93.6bn2022-04-01 → 2022-09-30Cons.Operating profit loss IFRS
Operating income¥49.1bn2022-07-01 → 2022-09-30dCons.Operating profit loss IFRS
Operating income¥70.7bn2021-04-01 → 2021-09-30Cons.Operating profit loss IFRS
Operating income¥44.7bn2021-07-01 → 2021-09-30dCons.Operating profit loss IFRS
Profit before tax¥89.3bn2022-04-01 → 2022-09-30Cons.Profit loss before tax IFRS
Profit before tax¥47.3bn2022-07-01 → 2022-09-30dCons.Profit loss before tax IFRS
Profit before tax¥141.7bn2021-04-01 → 2022-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥68.4bn2021-04-01 → 2021-09-30Cons.Profit loss before tax IFRS
Profit before tax¥43.0bn2021-07-01 → 2021-09-30dCons.Profit loss before tax IFRS
Net income (owners)¥66.8bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥42.0bn2022-07-01 → 2022-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥115.7bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥62.4bn2021-04-01 → 2021-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥43.7bn2021-07-01 → 2021-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income¥66.9bn2022-04-01 → 2022-09-30Cons.Profit loss IFRS
Net income¥42.0bn2022-07-01 → 2022-09-30dCons.Profit loss IFRS
Net income¥62.5bn2021-04-01 → 2021-09-30Cons.Profit loss IFRS
Net income¥43.8bn2021-07-01 → 2021-09-30dCons.Profit loss IFRS
Total assets¥1.49Tat 2022-09-30Cons.Assets IFRS
Total assets¥1.36Tat 2022-03-31Cons.Assets IFRS
Total assets¥1.19Tat 2021-09-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥842.0bnat 2022-09-30Cons.Liabilities IFRS
Total liabilities¥846.6bnat 2022-03-31Cons.Liabilities IFRS
Net assets / equity¥644.1bnat 2022-09-30Cons.Equity IFRS
Net assets / equity¥511.4bnat 2022-03-31Cons.Equity IFRS
Net assets / equity¥447.2bnat 2021-09-30Cons.Equity IFRS
Net assets / equity¥395.5bnat 2021-03-31dCons.Equity IFRS
Equity (owners)¥643.0bnat 2022-09-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥510.2bnat 2022-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥446.1bnat 2021-09-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥255.8bnat 2022-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥297.4bnat 2022-09-30Cons.Cash and cash equivalents IFRS (5-year summary)
Cash & equivalents¥302.6bnat 2022-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥193.4bnat 2021-09-30Cons.Cash and cash equivalents IFRS (5-year summary)
Operating cash flow¥6.3bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥169.7bn2021-04-01 → 2022-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥68.8bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥15.7bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥71.0bn2021-04-01 → 2022-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥50.5bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥35.5bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥40.7bn2021-04-01 → 2022-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥44.1bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥52.52022-04-01 → 2022-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥32.972022-07-01 → 2022-09-30dCons.Basic earnings loss per share IFRS
EPS (basic)¥90.222021-04-01 → 2022-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥48.532021-04-01 → 2021-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥342021-07-01 → 2021-09-30dCons.Basic earnings loss per share IFRS
EPS (diluted)¥52.452022-04-01 → 2022-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥32.932022-07-01 → 2022-09-30dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥90.172021-04-01 → 2022-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥48.512021-04-01 → 2021-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥33.982021-07-01 → 2021-09-30dCons.Diluted earnings loss per share IFRS
Equity ratio43.3%at 2022-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio37.6%at 2022-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio37.6%at 2021-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 10
SegmentItemPeriodValue
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥4.3bn
jpcrp040300-q2r_E02272-000Endoscopic Solutionsreportable segmentsegment profit2022-04-01 → 2022-09-30¥68.9bn
jpcrp040300-q2r_E02272-000Otherreportable segmentsegment profit2022-04-01 → 2022-09-30−¥788m
jpcrp040300-q2r_E02272-000Therapeutic Solutionsreportable segmentsegment profit2022-04-01 → 2022-09-30¥29.8bn
—segment totalsegment profit2022-04-01 → 2022-09-30¥97.9bn
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-09-30−¥20.1bn
jpcrp040300-q2r_E02272-000Endoscopic Solutionsreportable segmentsegment profit2021-04-01 → 2021-09-30¥61.6bn
jpcrp040300-q2r_E02272-000Otherreportable segmentsegment profit2021-04-01 → 2021-09-30−¥1.1bn
jpcrp040300-q2r_E02272-000Therapeutic Solutionsreportable segmentsegment profit2021-04-01 → 2021-09-30¥30.3bn
—segment totalsegment profit2021-04-01 → 2021-09-30¥90.8bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 766
ItemContextValueUnit
Effect of exchange rate changes on cash and cash equivalents IFRSPrior1YTDDuration1655000000JPY
Effect of exchange rate changes on cash and cash equivalents IFRSCurrentYTDDuration39615000000JPY
Net increase decrease in cash and cash equivalents IFRSPrior1YTDDuration-24043000000JPY
Net increase decrease in cash and cash equivalents IFRSCurrentYTDDuration-5183000000JPY
Cash and cash equivalents if different from bs balance IFRSPrior2YearInstant217478000000JPY
Cash and cash equivalents if different from bs balance IFRSPrior1YearInstant302572000000JPY
Cash and cash equivalents if different from bs balance IFRSPrior1QuarterInstant193435000000JPY
Cash and cash equivalents if different from bs balance IFRSCurrentQuarterInstant297389000000JPY
Sales to external customers IFRSPrior1YTDDuration_jpcrp040300-q2r_E02272-000EndoscopicSolutionsReportableSegmentMember220565000000JPY
Sales to external customers IFRSPrior1YTDDuration_jpcrp040300-q2r_E02272-000TherapeuticSolutionsReportableSegmentMember133101000000JPY
Sales to external customers IFRSPrior1YTDDuration_jpcrp040300-q2r_E02272-000OtherReportableSegmentMember6403000000JPY
Sales to external customers IFRSPrior1YTDDuration_ReportableSegmentsMember360069000000JPY
Sales to external customers IFRSPrior1YTDDuration_ReconcilingItemsMember－JPY
Sales to external customers IFRSPrior1YTDDuration360069000000JPY
Intersegment sales IFRSPrior1YTDDuration_jpcrp040300-q2r_E02272-000EndoscopicSolutionsReportableSegmentMember－JPY
Intersegment sales IFRSPrior1YTDDuration_jpcrp040300-q2r_E02272-000TherapeuticSolutionsReportableSegmentMember－JPY
Intersegment sales IFRSPrior1YTDDuration_jpcrp040300-q2r_E02272-000OtherReportableSegmentMember196000000JPY
Intersegment sales IFRSPrior1YTDDuration_ReportableSegmentsMember196000000JPY
Intersegment sales IFRSPrior1YTDDuration_ReconcilingItemsMember-196000000JPY
Intersegment sales IFRSPrior1YTDDuration－JPY
Net sales IFRSPrior1YTDDuration_jpcrp040300-q2r_E02272-000EndoscopicSolutionsReportableSegmentMember220565000000JPY
Net sales IFRSPrior1YTDDuration_jpcrp040300-q2r_E02272-000TherapeuticSolutionsReportableSegmentMember133101000000JPY
Net sales IFRSPrior1YTDDuration_jpcrp040300-q2r_E02272-000OtherReportableSegmentMember6599000000JPY
Net sales IFRSPrior1YTDDuration_ReportableSegmentsMember360265000000JPY
Net sales IFRSPrior1YTDDuration_ReconcilingItemsMember-196000000JPY
Net sales IFRSPrior1YTDDuration360069000000JPY
Operating profit loss IFRSPrior1YTDDuration_jpcrp040300-q2r_E02272-000EndoscopicSolutionsReportableSegmentMember61645000000JPY
Operating profit loss IFRSPrior1YTDDuration_jpcrp040300-q2r_E02272-000TherapeuticSolutionsReportableSegmentMember30262000000JPY
Operating profit loss IFRSPrior1YTDDuration_jpcrp040300-q2r_E02272-000OtherReportableSegmentMember-1136000000JPY
Operating profit loss IFRSPrior1YTDDuration_ReportableSegmentsMember90771000000JPY
Operating profit loss IFRSPrior1YTDDuration_ReconcilingItemsMember-20109000000JPY
Operating profit loss IFRSPrior1YTDDuration70662000000JPY
Finance income IFRSPrior1YTDDuration594000000JPY
Finance costs IFRSPrior1YTDDuration2834000000JPY
Profit loss before tax IFRSPrior1YTDDuration68422000000JPY
Share of profit loss of investments accounted for using equity method IFRSPrior1YTDDuration_jpcrp040300-q2r_E02272-000EndoscopicSolutionsReportableSegmentMember446000000JPY
Share of profit loss of investments accounted for using equity method IFRSPrior1YTDDuration_jpcrp040300-q2r_E02272-000TherapeuticSolutionsReportableSegmentMember-47000000JPY
Share of profit loss of investments accounted for using equity method IFRSPrior1YTDDuration_jpcrp040300-q2r_E02272-000OtherReportableSegmentMember－JPY
Share of profit loss of investments accounted for using equity method IFRSPrior1YTDDuration_ReportableSegmentsMember399000000JPY
Share of profit loss of investments accounted for using equity method IFRSPrior1YTDDuration_ReconcilingItemsMember－JPY
Share of profit loss of investments accounted for using equity method IFRSPrior1YTDDuration399000000JPY
Depreciation and amortization operating expenses IFRSPrior1YTDDuration_jpcrp040300-q2r_E02272-000EndoscopicSolutionsReportableSegmentMember16261000000JPY
Depreciation and amortization operating expenses IFRSPrior1YTDDuration_jpcrp040300-q2r_E02272-000TherapeuticSolutionsReportableSegmentMember7966000000JPY
Depreciation and amortization operating expenses IFRSPrior1YTDDuration_jpcrp040300-q2r_E02272-000OtherReportableSegmentMember751000000JPY
Depreciation and amortization operating expenses IFRSPrior1YTDDuration_ReportableSegmentsMember24978000000JPY
Depreciation and amortization operating expenses IFRSPrior1YTDDuration_ReconcilingItemsMember3511000000JPY
Depreciation and amortization operating expenses IFRSPrior1YTDDuration28489000000JPY
Impairment losses pl IFRSPrior1YTDDuration_jpcrp040300-q2r_E02272-000EndoscopicSolutionsReportableSegmentMember1775000000JPY
Impairment losses pl IFRSPrior1YTDDuration_jpcrp040300-q2r_E02272-000TherapeuticSolutionsReportableSegmentMember－JPY
Impairment losses pl IFRSPrior1YTDDuration_jpcrp040300-q2r_E02272-000OtherReportableSegmentMember－JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-03-31pass
balance sheet identityconsolidated 2022-09-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2021-07-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-07-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-09-30pass